Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New injection shows promise for reducing excessive drooling

NCT ID NCT01994109

Symptom relief Sponsor: Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 study tested whether injections of MYOBLOC (a botulinum toxin type B) into the salivary glands can safely reduce troublesome drooling in adults. 187 participants received either MYOBLOC or a placebo. The main goals were to measure changes in saliva flow and overall improvement at 4 weeks. Results showed that MYOBLOC effectively decreased saliva production and improved symptoms compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MYOBLOC (rimabotulinumtoxinB, botulinum toxin type B)
What this could lead to
If it works, this could provide a safe and effective treatment option for adults with troublesome drooling due to various medical conditions.
What could go wrong
This is a completed Phase 3 trial, so results are more reliable, but individual responses may vary and there are risks like dry mouth or injection site reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

187 people

The number who actually took part.

Start date

Nov 2013

Finished

Jan 2017

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Seeking treatment for troublesome sialorrhea for at least 3 months that is occurring secondary to any disorder or related to any cause * Investigator sites will review entire list of inclusion criteria with potential subjects Exclusion Criteria: * Any known prior exposure to botulinum toxin type B, or known adverse reaction or sensitivity to botulinum toxin type A, or known sensitivity to any of the MYOBLOC solution components. * Prior botulinum toxin treatment to the salivary glands at any time * Investigator sites will review entire list of exclusion criteria with potential subjects

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sialorrhea are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis Parkinson disease Sialorrhea stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sialorrhea

Contacts and locations

Locations

  • Study site

    Loma Linda, California, 92354, United States

  • Study site

    Los Angeles, California, 90033, United States

  • Study site

    National City, California, 91950, United States

  • Study site

    Aurora, Colorado, 80045, United States

  • Study site

    Washington D.C., District of Columbia, 20007, United States

  • Study site

    Boca Raton, Florida, 33486, United States

  • Study site

    Port Charlotte, Florida, 33980, United States

  • Study site

    Carmel, Indiana, 46032, United States

  • Study site

    Baltimore, Maryland, 21287, United States

  • Study site

    Elkridge, Maryland, 21075, United States

  • Study site

    Detroit, Michigan, 48334, United States

  • Study site

    St Louis, Missouri, 63110, United States

  • Study site

    Edison, New Jersey, 08818, United States

  • Study site

    Albany, New York, 12208, United States

  • Study site

    New York, New York, 10003, United States

  • Study site

    Cincinnati, Ohio, 45219, United States

  • Study site

    Tulsa, Oklahoma, 74136, United States

  • Study site

    Port Royal, South Carolina, 29935, United States

  • Study site

    Cordova, Tennessee, 38018, United States

  • Study site

    Houston, Texas, 77030, United States

  • Study site

    San Antonio, Texas, 78229, United States

  • Study site

    Salt Lake City, Utah, 84132, United States

  • Study site

    Kirkland, Washington, 98034, United States

  • Study site

    Tacoma, Washington, 98409, United States

  • Study site

    Irkutsk, Irkutsk Oblast, 664079, Russia

  • Study site

    Vsevolozhsk, Leningradskaya Oblast', 188643, Russia

  • Study site

    Saint Petersburg, Petrodvorets, 198510, Russia

  • Study site

    Krasnoyarsk, 660037, Russia

  • Study site

    Dnipropetrovsk, 49027, Ukraine

  • Study site

    Ivano-Frankivsk, 76008, Ukraine

  • Study site

    Kharkiv, 61068, Ukraine

  • Study site

    Lviv, 79010, Ukraine

  • Study site

    Rivne, 33010, Ukraine

  • Study site

    Uzhhorod, 88018, Ukraine

More trials for these conditions

Other studies related to the condition(s) this trial covers.